Opinion

$Mostafa Faisal: Primary Refractory AML and Allo-HCT – A 10-Year Retrospective Study from Japan$

medicaltourismco.com

Jun 19, 2025, 15:47

Mostafa Faisal: Primary Refractory AML and Allo-HCT – A 10-Year Retrospective Study from Japan

Mostafa Faisal, Adjunct Assistant Professor at Alfaisal University, shared a post on X:

“Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory AML (2013–2022): A retrospective study by the adult AML working group of the Japanese Society for Transplantation and Cellular Therapy

Primary Refractory AML and Allo-HCT (n=2600, Japan 2013–2022)

3-yr OS: 28.5% | LFS: 24.4%
Relapse: 49.8% | NRM: 25.8%

Worse outcomes with:
– Age ≥50
– PS ≥2
– Adverse cytogenetics
– EM disease
– PB blasts ≥10%.”

Title: Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory acute myeloid leukaemia (2013–2022): A retrospective study by the adult acute myeloid leukaemia working group of the Japanese Society for Transplantation and Cellular Therapy

Authors: Takaaki Konuma, Yoshimitsu Shimomura, Shohei Mizuno, Satoshi Yamasaki, Shunsuke Yui, Naoyuki Uchida, Noriko Doki, Masatsugu Tanaka, Satoshi Yoshihara, Tetsuya Eto, Yuta Katayama, Yuna Katsuoka, Masahito Tokunaga, Shuichi Ota, Mamiko Sakata-Yanagimoto, Kazuya Ishiwata, Yoshinobu Kanda, Toshiro Kawakita, Makoto Onizuka, Junya Kanda, Takahiro Fukuda, Yoshiko Atsuta, Masamitsu Yanada

Read Full Article.

$Mostafa Faisal: Primary Refractory AML and Allo-HCT - A 10-Year Retrospective Study from Japan 1$

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

Opinion

OncoDaily

Opinion

Mostafa Faisal: Primary Refractory AML and Allo-HCT – A 10-Year Retrospective Study from Japan

“Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory AML (2013–2022): A retrospective study by the adult AML working group of the Japanese Society for Transplantation and Cellular Therapy

Primary Refractory AML and Allo-HCT (n=2600, Japan 2013–2022)

3-yr OS: 28.5% | LFS: 24.4%
Relapse: 49.8% | NRM: 25.8%

Worse outcomes with:
– Age ≥50
– PS ≥2
– Adverse cytogenetics
– EM disease
– PB blasts ≥10%.”

Opinion

OncoDaily

Opinion

Mostafa Faisal: Primary Refractory AML and Allo-HCT – A 10-Year Retrospective Study from Japan

“Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory AML (2013–2022): A retrospective study by the adult AML working group of the Japanese Society for Transplantation and Cellular Therapy

Primary Refractory AML and Allo-HCT (n=2600, Japan 2013–2022)

3-yr OS: 28.5% | LFS: 24.4% Relapse: 49.8% | NRM: 25.8%

Worse outcomes with: – Age ≥50 – PS ≥2 – Adverse cytogenetics – EM disease – PB blasts ≥10%.”

3-yr OS: 28.5% | LFS: 24.4%
Relapse: 49.8% | NRM: 25.8%

Worse outcomes with:
– Age ≥50
– PS ≥2
– Adverse cytogenetics
– EM disease
– PB blasts ≥10%.”